These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 35361730)
1. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer. Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833 [TBL] [Abstract][Full Text] [Related]
3. Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients. Cai S; Zhao M; Yang G; Li C; Hu M; Yang L; Xing L; Sun X Int Immunopharmacol; 2024 Aug; 137():112434. PubMed ID: 38889507 [TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672 [TBL] [Abstract][Full Text] [Related]
5. Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis. Zhao S; Liu Y; Ding L; Zhang C; Ye J; Sun K; Song W; Cai S; He Y; Peng J; Xu J J Pathol Clin Res; 2024 May; 10(3):e12378. PubMed ID: 38778559 [TBL] [Abstract][Full Text] [Related]
6. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929 [TBL] [Abstract][Full Text] [Related]
7. Dynamic alteration and prognostic significance of tumor-associated CD68 Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. Tang X; Li M; Wu X; Guo T; Zhang L; Tang L; Jia F; Hu Y; Zhang Y; Xing X; Shan F; Gao X; Li Z Oncoimmunology; 2022; 11(1):2135819. PubMed ID: 36268179 [TBL] [Abstract][Full Text] [Related]
9. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Park JH; Jang M; Tarhan YE; Katagiri T; Sasa M; Miyoshi Y; Kalari KR; Suman VJ; Weinshilboum R; Wang L; Boughey JC; Goetz MP; Nakamura Y Int J Oncol; 2016 Aug; 49(2):471-8. PubMed ID: 27278091 [TBL] [Abstract][Full Text] [Related]
10. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Waks AG; Stover DG; Guerriero JL; Dillon D; Barry WT; Gjini E; Hartl C; Lo W; Savoie J; Brock J; Wesolowski R; Li Z; Damicis A; Philips AV; Wu Y; Yang F; Sullivan A; Danaher P; Brauer HA; Osmani W; Lipschitz M; Hoadley KA; Goldberg M; Perou CM; Rodig S; Winer EP; Krop IE; Mittendorf EA; Tolaney SM Clin Cancer Res; 2019 Aug; 25(15):4644-4655. PubMed ID: 31061067 [TBL] [Abstract][Full Text] [Related]
11. Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma. Sugawara K; Fukuda T; Murakami C; Oka D; Yoshii T; Amori G; Ishibashi K; Kobayashi Y; Hara H; Kanda H; Motoi N Cancer Sci; 2024 Aug; 115(8):2819-2830. PubMed ID: 38693726 [TBL] [Abstract][Full Text] [Related]
12. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer. Heeren AM; van Luijk IF; Lakeman J; Pocorni N; Kole J; de Menezes RX; Kenter GG; Bosse T; de Kroon CD; Jordanova ES Cancer Immunol Immunother; 2019 Nov; 68(11):1759-1767. PubMed ID: 31616965 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594 [No Abstract] [Full Text] [Related]
15. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Kumar T; Hobbs E; Yang F; Chang JT; Contreras A; Cuentas ERP; Garber H; Lee S; Lu Y; Scoggins ME; Adrada BE; Whitman GJ; Arun BK; Mittendorf EA; Litton JK Clin Cancer Res; 2022 Sep; 28(17):3669-3676. PubMed ID: 35736816 [TBL] [Abstract][Full Text] [Related]
16. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1 Liang H; Li H; Xie Z; Jin T; Chen Y; Lv Z; Tan X; Li J; Han G; He W; Qiu N; Jiang M; Zhou J; Xia H; Zhan Y; Cui L; Guo W; Huang J; Zhang X; Wu YL Thorac Cancer; 2020 Oct; 11(10):2941-2954. PubMed ID: 32894006 [TBL] [Abstract][Full Text] [Related]
17. Immunological impact of chemotherapy on the tumor microenvironment in gastric cancer. Wei Q; Xu Q; Yuan X; Li JJ; Chen L; Luo C; Zhu X; Ying JE J Surg Oncol; 2021 May; 123(8):1708-1715. PubMed ID: 33684248 [TBL] [Abstract][Full Text] [Related]
18. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669 [TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519 [TBL] [Abstract][Full Text] [Related]
20. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]